Does uterine hyperstimulation cause amniotic fluid embolism?
A question that matters for this checklist, because the answer determines whether a clinician standing at the bedside of a woman with sudden hypertonus and fetal bradycardia should reach for a tocolytic. They should not.
Short answer
The association appears throughout the textbook literature and largely disappears in the controlled data. The specific claim that excessive uterine activity causes AFE does not survive scrutiny, and the causal direction is probably backwards.
Where “tetanic contraction” as a risk factor comes from
It is a legacy claim. Reviews still list strong, frequent or tetanic uterine contractions among the risk factors, but the citations lead back to case series and autopsy reports from the pre-1990 era. No controlled study of AFE has ever used tachysystole, Montevideo units or hypertonus as an exposure variable. The claim has never been tested. It has only been repeated.
Note what is absent from the risk-factor list in the most rigorous evidence-based review of AFE (ref 24): no tumultuous labour, no hypertonus, no tachysystole. What it lists instead is advanced maternal age, placental abnormalities, operative deliveries, eclampsia, polyhydramnios, cervical laceration and uterine rupture — a list of portals of entry.
What the controlled data show
| Exposure | Kramer, Canada, 3M births (ref 22) | Abenhaim, US, 3M births (ref 23) | Fitzpatrick, UKOSS (ref 25) | Fitzpatrick, INOSS 5 countries (ref 11) |
|---|---|---|---|---|
| Induction, any method | aOR 1.8 (1.3–2.7) | aOR 1.5 (0.9–2.3), NS | raised | raised |
| Prostaglandin induction | — | — | aOR 6.46 (3.47–12.01) | aOR 2.46 (1.17–5.15) |
| Oxytocin in labour | — | — | aOR 2.80 (1.48–5.29) | aOR 1.31 (0.83–2.07), NS |
| Prostaglandin + oxytocin | — | — | aOR 2.43 | — |
| Dystocia | aOR 0.6 (0.4–0.8) | aOR 0.4 (0.2–0.7) | — | — |
Oxytocin is not associated with AFE. In the largest and methodologically cleanest study — pooled prospective population-based surveillance from five countries with agreed case definitions — the odds of AFE were significantly raised with prostaglandin induction but not with oxytocin use in labour (ref 11). Oxytocin is the agent that produces tachysystole, it is titratable, and exposure is dose-dependent and prolonged. If contraction force were the causal pathway, oxytocin is where the signal would be. It is not there.
The gradient runs the wrong way. In UKOSS, prostaglandin without oxytocin carried the highest odds, oxytocin alone lower, and both together lower still (ref 25). Adding the more potent uterotonic lowered the odds. Under a hyperstimulation model, prostaglandin plus oxytocin should be the worst cell in the table. It is the best of the three.
Dystocia is protective, consistently. Both three-million-birth cohorts found dystocia significantly protective (refs 22, 23, tabulated in ref 24). Dystocia is the clinical antonym of tumultuous labour. A hypothesis that says forceful labour causes AFE has to explain why obstructed, inefficient labour is protective in six million births.
The original registry found nothing. Clark's 1995 national registry — the very case series usually cited for the tumultuous-labour claim — reported no correlation with either prolonged labour or oxytocin use (ref 21).
The causal direction is probably backwards
SMFM has said so since 2016: abnormalities of uterine tone, hypo- or hypertonic, described commonly in cases of AFE may be the consequence of uterine hypoperfusion secondary to profound maternal shock and hypoxia with massive catecholamine release, rather than the cause (ref 2). The same guideline describes the antepartum presentation as decelerations, loss of variability and terminal bradycardia as oxygenated blood is shunted away from the uterus, with catecholamine-induced uterine hypertonus causing a further decline in uterine perfusion.
So the hypertonic contraction observed at the onset of an AFE is a sign of the event in progress, not its trigger. It has the same status as the fetal bradycardia beside it on the strip.
There is a further physiological problem with the mechanical model, flagged here as reasoning rather than as a sourced claim: during a tetanic contraction, intrauterine pressure exceeds uterine venous pressure and uteroplacental venous drainage stops. A pressure gradient that closes the exit route is a poor candidate for a mechanism that forces material into the venous circulation.
The pathophysiology has in any case moved away from mechanics entirely. Amniotic fluid is soluble in blood and cannot obstruct; the quantities of fetal debris involved are too small to occlude enough pulmonary vasculature to explain the haemodynamics (ref 4); squamous cells are not the obstructing agent (ref 26). Once the syndrome is immune rather than embolic, contraction force loses its role. What remains explanatory is the portal of entry — which is exactly what the surviving risk factors describe.
Should the checklist include preventing hyperstimulation?
No — and adding it would make the document worse in three ways.
It is the wrong document. The SMFM statement is explicitly scoped to initial management on the labour and delivery unit after the event has declared itself. Prevention belongs in a labour-management guideline. A cognitive aid used during a resuscitation should contain only actions that can be taken in the next four minutes.
The evidence does not support it. Recommending an intervention to prevent AFE requires believing that uterine activity is on the causal path. The oxytocin data argue against it.
It would be actively dangerous. A clinician who believes hypertonus causes AFE, standing at the bedside of a woman with sudden hypertonus and fetal bradycardia, will reach for a tocolytic. Published case reports describe exactly this sequence — terbutaline given for fetal bradycardia during cervical ripening, followed within minutes by maternal deterioration and emergency caesarean. Tocolysis in a patient whose actual problem is acute pulmonary hypertension, right ventricular failure and impending cardiovascular collapse treats the epiphenomenon and worsens the disease.
1. Uterine hypertonus and fetal bradycardia at onset are signs of the AFE, not causes of it. Do not give tocolytics — terbutaline, nitroglycerin or magnesium — in suspected AFE. They worsen hypotension and right ventricular failure.
2. Stop an oxytocin infusion already running at the moment of collapse, then restart it after delivery for atony prophylaxis — a sequencing point the current checklist leaves ambiguous, since it says to give oxytocin prophylaxis without addressing an infusion in progress.
Both appear on the live checklist, clearly marked as LiveEvidence annotations rather than SMFM text.
Uncertainty, stated
Absence of evidence is not evidence of absence. Tachysystole has never been measured as an exposure, so the honest statement is unsupported, not refuted. The induction association is real, consistent across five countries and unexplained; confounding by indication is severe, since prostaglandin ripening selects for post-dates, intrauterine fetal death and unfavourable cervices. Prostaglandins also cause tachysystole, so a contraction-mediated pathway is not formally excluded — the oxytocin null result is the strongest single argument against it, not a proof. Ref 28, a methodological case study of how the uterine-stimulant association was constructed, is listed as a pointer only; its full text has not been read for this page and the direction of its argument is not characterised here.